Recombinant Human Interleukin-36 alpha/IL-36 alpha
- SKU:
- RPES6225
- Product Type:
- Recombinant Protein
- Species:
- Human
Frequently bought together:
Description
Product Name: | Recombinant Human Interleukin-36 alpha/IL-36 alpha |
Product Code: | RPES6225 |
Size: | 20µg |
Species: | Human |
Expression Host: | E.coli |
Synonyms: | Interleukin-36 Alpha, FIL1 Epsilon, Interleukin-1 Epsilon, IL-1 Epsilon, Interleukin-1 Family Member 6, IL-1F6, IL36A, FIL1E, IL1E, IL1F6 |
Mol Mass: | 17.1 kDa |
AP Mol Mass: | 17 kDa |
Tag: | None |
Purity: | > 95 % as determined by reducing SDS-PAGE. |
Endotoxin Level: | < 1.0 EU per μg of the protein as determined by the LAL method. |
Bio Activity: | Measured in a cell proliferation assay using A-431 Human epithelial carcinoma cells. The ED50 for this effect is 12.0 ng/ml. |
Sequence: | Lys6-Phe158 |
Accession: | Q9UHA7 |
Storage: | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. |
Shipping: | This product is provided as lyophilized powder which is shipped with ice packs. |
Formulation: | Lyophilized from a 0.2 μm filtered solution of 50mM Tris-HCl, 150mM NaCl, 1 mM EDTA, 0.02% Tween 20, pH 8.0. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buff |
Reconstitution: | Please refer to the printed manual for detailed information. |
Background: | Human Interleukin-36α (IL-36α) is a secreted cytokine that belongs to the Interleukin 1 cytokine family. IL-36α is expressed in the immune system and the fetal brain, but not in other tissues or multiple hematopoietic cell lines. IL-36α is the only IL-1 family member found to be expressed on T-cells. IL-36α and IL-1F8 are involved in the regulation of adipose tissue gene expression. Importantly, IL-36α inhibits PPARγ expression, which may lead to a reduction in adipocyte differentiation suggesting metabolic effects of this cytokine. IL-36α, along with IL-1F8 and IL-1F9, has been shown to act as an agonist by activating the pathway involving NFκB and MAPK in an IL-1Rrp2 dependent manner. This suggest that IL-36α may signal in a similar fashion to IL-1 and IL-18 in having a binding receptor which upon ligation, recruits a second receptor as a signaling component, forming an active heterodimeric receptor complex. |